Product Description
Mechanisms of Action: B2 Agonist
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alkermes
Company Location: DUBLIN 4 L2 00000
Company CEO: Richard F. Pops
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Brain Stem Cancer
Phase 1: Brain Stem Cancer|Glioma|Medulloblastoma|Meningitis, Cryptococcal|HIV Infections|Acquired Immunodeficiency Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ADVL0012 | P1 |
Completed |
Glioma|Brain Stem Cancer |
2005-01-01 |
|
CDR0000066169 | P2 |
Completed |
Brain Stem Cancer |
None |
|
96-C-0068 | P1 |
Completed |
Medulloblastoma|Glioma |
None |
|
131A | P1 |
Completed |
Meningitis, Cryptococcal|HIV Infections|Acquired Immunodeficiency Syndrome |
None |